Related Experiment Videos
Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder
Gagan Joshi1, Joseph Biederman, Janet Wozniak
1Pediatric Psychopharmacology Research Department, Massachusetts General Hospital, USA. Joshi.Gagan@mgh.harvard.edu
Objective:
To assess the impact of comorbid autism spectrum disorders (ASD) on the response to second-generation antipsychotics (SGA) in pediatric bipolar disorder (BPD).
Methods:
Secondary analysis of identically designed 8-week open-label trials of SGA monotherapy (risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole) in youth with BPD.
Results:
Of the 151 BPD subjects 15% (n= 23) met criteria for comorbid ASD. There were no differences in the rate of antimanic response (YMRS change ≥30% or CGI-Improvement ≤2: 65% vs. 69%; P= 0.7) in the presence of comorbid ASD.
Conclusion:
No difference observed in the rate of antimanic response or tolerability to SGA monotherapy in the presence of ASD comorbidity.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Psychosis and Antipsychotic Drugs: Overview
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
Bipolar Disorder